Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee.
Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination.
To determine whether survival was affected by sequentially more stringent definitions of pN staging quality in a cohort of patients with NSCLC after resection with curative intent.
This observational study used the Mid-South Quality of Surgical Resection cohort, a population-based database of lung cancer resections with curative intent. A total of 2047 consecutive patients who underwent surgical resection at 11 hospitals with at least 5 annual lung cancer resections in 4 contiguous US Dartmouth hospital referral regions in northern Mississippi, eastern Arkansas, and western Tennessee (>90% of the eligible population) were included. Resections were performed from January 1, 2009, through January 25, 2016. Survival was evaluated with the Kaplan-Meier method and Cox proportional hazards models.
Eight sequentially more stringent pN staging quality strata included the following: all patients (group 1); those with complete resections only (group 2); those with examination of at least 1 mediastinal lymph node (group 3); those with examination of at least 10 lymph nodes (group 4); those with examination of at least 3 hilar or intrapulmonary and at least 3 mediastinal lymph nodes (group 5); those with examination of at least 10 lymph nodes, including at least 1 mediastinal lymph node (group 6); those with examination of at least 1 hilar or intrapulmonary and at least 3 mediastinal nodal stations (group 7); and those with examination of at least 1 hilar or intrapulmonary lymph node, at least 10 total lymph nodes, and at least 3 mediastinal nodal stations (group 8).
N category-stratified overall survival.
Of the total 2047 patients (1046 men [51.1%] and 1001 women [48.9%]; mean [SD] age, 67.0 [9.6] years) included in the analysis, the eligible analysis population ranged from 541 to 2047, depending on stringency. Sequential improvement in the N category-stratified 5-year survival of pN0 and pN1 tumors was found from the least stringent group (0.63 [95% CI, 0.59-0.66] for pN0 vs 0.46 [95% CI, 0.38-0.54] for pN1) to the most stringent group (0.71 [95% CI, 0.60-0.79] for pN0 vs 0.60 [95% CI, 0.43-0.73] for pN1). The pN1 cohorts with 3 or more mediastinal nodal stations examined had the most striking survival improvements. More stringently defined mediastinal nodal examination was associated with better separation in survival curves between patients with pN1 and pN2 tumors.
The prognostic value of pN stratification depends on the thoroughness of examination. Differences in thoroughness of nodal staging may explain a large proportion of intercontinental survival differences. More thorough nodal examination practice must be disseminated to improve the prognostic value of the TNM staging system. Future updates of the TNM staging system should incorporate more quality restraints.
病理性淋巴结分期是非小细胞肺癌(NSCLC)可切除患者最重要的预后因素。国际肺癌研究协会 NSCLC 分期项目揭示了 N 分期分层生存的洲际差异。这些差异可能不仅表明癌症生物学方面的差异,还表明淋巴结检查的彻底性不同。
在接受根治性切除的 NSCLC 患者队列中,确定随着 pN 分期质量的定义逐渐严格,生存是否受到影响。
本观察性研究使用了中南部手术切除质量队列,这是一个基于人群的肺癌根治性切除数据库。共纳入了 11 家医院的 2047 例连续患者,这些患者在密西西比州北部、阿肯色州东部和田纳西州西部的 4 个相邻的达特茅斯医院转诊区进行了至少 5 例年度肺癌切除术的手术切除(合格人群的 90%以上)。切除术于 2009 年 1 月 1 日至 2016 年 1 月 25 日进行。采用 Kaplan-Meier 方法和 Cox 比例风险模型评估生存情况。
8 个逐渐严格的 pN 分期质量分层包括以下内容:所有患者(第 1 组);仅行完全切除术的患者(第 2 组);至少检查 1 个纵隔淋巴结的患者(第 3 组);至少检查 10 个淋巴结的患者(第 4 组);至少检查 3 个肺门或肺内和至少 3 个纵隔淋巴结的患者(第 5 组);至少检查 10 个淋巴结,包括至少 1 个纵隔淋巴结的患者(第 6 组);至少检查 1 个肺门或肺内和至少 3 个纵隔淋巴结站的患者(第 7 组);以及至少检查 1 个肺门或肺内淋巴结、至少 10 个总淋巴结和至少 3 个纵隔淋巴结站的患者(第 8 组)。
N 分期分层的总生存率。
在纳入分析的 2047 例患者(1046 名男性[51.1%]和 1001 名女性[48.9%];平均[标准差]年龄,67.0[9.6]岁)中,根据严格程度,合格分析人群范围从 541 到 2047 例。发现 pN0 和 pN1 肿瘤的 N 分期分层 5 年生存率从最宽松的组(pN0 为 0.63[95%CI,0.59-0.66];pN1 为 0.46[95%CI,0.38-0.54])逐渐提高到最严格的组(pN0 为 0.71[95%CI,0.60-0.79];pN1 为 0.60[95%CI,0.43-0.73])。检查了 3 个或更多纵隔淋巴结站的 pN1 队列的生存改善最为显著。更严格定义的纵隔淋巴结检查与 pN1 和 pN2 肿瘤患者的生存曲线之间更好的分离相关。
pN 分层的预后价值取决于检查的彻底性。淋巴结分期彻底性的差异可能解释了洲际生存差异的很大一部分。必须传播更彻底的淋巴结检查实践,以提高 TNM 分期系统的预后价值。未来 TNM 分期系统的更新应纳入更多质量限制。